{"id":130428,"date":"2026-09-14T11:27:27","date_gmt":"2026-09-14T11:27:27","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/130428\/"},"modified":"2026-09-14T11:27:27","modified_gmt":"2026-09-14T11:27:27","slug":"novartis-shares-fall-as-del-desiran-flunks-phase-3-myotonic-dystrophy-trial","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/130428\/","title":{"rendered":"Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial"},"content":{"rendered":"<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/ddd3d864545498306f0c7094ccb53d96753a00373ba4279a1f7a31782224be17\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fproactive_us_504%2F69858224b7aa75602ecf12d392cec13c.jpg\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial\" height=\"540\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial Proactive uses images sourced from Shutterstock           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/finance.yahoo.com\/quote\/NVS\" data-ylk=\"slk:Novartis%20AG%20(ADR)%20(NYSE%3ANVS);elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Novartis AG (ADR) (NYSE:NVS)&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"nofollow noopener\">Novartis AG (ADR) (NYSE:NVS)<\/a> shares fell as much as 10% after the company&#8217;s del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR study evaluating the drug in myotonic dystrophy type 1.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The study did not show a statistically significant improvement over placebo on video hand opening time, a novel measure of hand myotonia that served as the trial&#8217;s primary endpoint.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis said it is evaluating the full HARBOR dataset and will engage with health authorities to determine the most appropriate development path for del-desiran.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The setback marks Novartis&#8217; second major late-stage trial failure in a matter of days, following the recent failure of its cardiovascular drug pelacarsen.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The read-through hit other companies developing treatments for myotonic dystrophy type 1. Dyne Therapeutics shares dropped roughly 21%, while <a href=\"https:\/\/finance.yahoo.com\/quote\/SRPT\" data-ylk=\"slk:Sarepta%20Therapeutics%20Inc%20(NASDAQ%3ASRPT);elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Sarepta Therapeutics Inc (NASDAQ:SRPT)&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"nofollow noopener\">Sarepta Therapeutics Inc (NASDAQ:SRPT)<\/a> fell about 10%, as investors reassess whether targeting toxic DMPK RNA will reliably translate into functional improvement for patients.  <\/p>\n","protected":false},"excerpt":{"rendered":"Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial Proactive uses images sourced from Shutterstock Novartis&hellip;\n","protected":false},"author":2,"featured_media":130429,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[62201,206,6650],"class_list":["post-130428","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-myotonic-dystrophy","tag-novartis","tag-primary-endpoint"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117269158007425648","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/130428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=130428"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/130428\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/130429"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=130428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=130428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=130428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}